17 Nov New Drug Might Suppress Both COVID-19 and Cancer Growth
MedicalResearch.com Interview with:
Amy S. Lee, Ph.D.Professor of Biochemistry and Molecular Medicine USC/Norris Cancer Center Los Angeles, CA 90033
MedicalResearch.com: What is the background for this study?
Response: Trying to find stable host cell targets to combat SARS-CoV-2 instead of chasing after the ever-mutating virus.
MedicalResearch.com: What should readers take away from your report?
Response: When SARS-CoV-2 infects the host cell, it creates stress leading to higher production of GRP78. Blocking GRP78 reduces the ability of the virus to multiple and infect other cells.
MedicalResearch.com: What recommendations do you have for future research as a results of this study?
Response: More pre-clinical studies and drug development to translate these basic science discoveries into practice.
Disclosures? Amy S. Lee is a member of the scientific advisory board of BiPER Therapeutics.
Shin, WJ., Ha, D.P., Machida, K. et al. The stress-inducible ER chaperone GRP78/BiP is upregulated during SARS-CoV-2 infection and acts as a pro-viral protein. Nat Commun 13, 6551 (2022). https://doi.org/10.1038/s41467-022-34065-3
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on November 17, 2022 by Marie Benz MD FAAD